TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Full Body Massage
Description: Applying massage after phototherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Full Body Massage
Description: Oil Full Body Massage
Study: NCT05968742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence of oral hygiene on select teeth
Description: Study participants abstain from oral hygiene on a select set of four teeth for a period of 21 days
Study: NCT05403333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: utidelone
Description: Utidelone Injection: 65 mg/m2/day, IV on day 1, 8, and 15 every 28 days
Study: NCT06370273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 10mg once daily via oral ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 10mg once daily via oral ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 2.5mg twice daily via oral ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 2.5mg twice daily via oral ingestion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Injectable Solution
Description: 40mg once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Injectable Solution
Description: 40mg once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin Injectable Solution
Description: 4500 IU once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin Injectable Solution
Description: 4500 IU once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin Injectable Solution
Description: 5000 IU once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin Injectable Solution
Description: 5000 IU once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Injectable Product
Description: 2.5 mg once daily via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux Injectable Product
Description: 2.5 mg once daily via subcutaneous injection
Study: NCT06288477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A cotton pellet moistened with full-strength FC
Description: A cotton pellet moistened with full-strength FC will be placed for 5 minutes on the amputated pulp, after reaching hemostasis. The pulp stumps will be then covered by IRM (Intermediate Restorative Material).
Study: NCT05504083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group. Part B: Subjects will be assigned to D-0120 group 3.
Study: NCT06288477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Putty
Description: Following removal of the coronal pulp with a round bur and hemostasis, the pulp stumps in the study group will be covered with Neo-Putty ® according to the manufacturer's instructions. Neo-Putty will be placed in the prepared cavity, and then covered with a reinforced Zinc Oxide-Eugenol (IRM, Bayer-Leverkussen, Germany).
Study: NCT05504083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzbromarone
Description: Part A: Randomized in a 1:1:1 ratio through the randomization system, and assigned to D-0120 group 1, D-0120 group 2 or benzbromarone control group.
Study: NCT04941378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intraoperative imaging camera system
Description: intraoperative imaging camera system
Study: NCT05153733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIFRAM implant
Description: Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.
Study: NCT05922436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLG2071
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleviprex®
Description: intravenous injection
Study: NCT05205460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based telehealth exercise training program
Description: A home-based exercise mobile app will be offered combined with the heart rate sensing clothes to each participant in the group of home-based telehealth exercise training program. The mobile app provides auto-feedback of heart rate at each exercise training session through the heart rate sensing clothes and alarm function identifying individuals' appropriate exercise intensity (target heart rate) during their exercise based on their exercise prescription calculated and set up inside the app. After completing each exercise training session, the record of training time and heart rate response is simultaneously uploaded to the cloud system of the medical center through the heart rate sensing clothes. The experienced and well-trained nurse checked the cloud system data to monitor participants' adherence to exercise training. In addition, online communication is enabled using LINE software, which provided a platform for patients and researchers to interact with each other through messaging.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and self-exercise
Description: The participants will receive a exercise prescription suggestion. Then, they will maintain their routine outpatient follow-up per month and usual lifestyles with weekly reminders.
Study: NCT06245044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MI Help
Description: Participants will complete the medication verification task without any MI help

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #1
Description: Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #1
Description: Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR
Study: NCT06245044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #1
Description: Participants will receive MI in the form of a pop-up message if their decision differs from the MI's determination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #2
Description: MI help will be displayed concurrently with the filled and reference images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #2
Description: MI help will be displayed concurrently with the filled and reference images.
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR
Study: NCT06245044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scenario #2
Description: MI help will be displayed concurrently with the filled and reference images.
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR
Description: 200MBq of the above named radiotracer will be administered for PET-MR

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Echocardiogram at baseline and 1 year follow-up
Study: NCT04255849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Description: Gardasil-9 HPV vaccine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline Placebo
Study: NCT06017427

Intervention type: OTHER
Intervention: Questionnaires
Description: Submission of several questionnaires (Quality of Life and clinical scores) at three time points: before initiation of Dupilumab, after 6 months of Dupilumab treatment, and 6 months after stopping Dupilumab treatment
Study: NCT05676008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microdosing of mindfulness
Description: The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.
Study: NCT04983940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jatenzo
Description: 237 mg soft gel capsule taken twice a day by mouth with food.
Study: NCT06482606

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flickering Checkerboard Stimulation
Description: This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flickering Checkerboard Stimulation
Description: This visual stimulation is a succession of alternating black and white squares on a small monitor in the scanner, the black and white checkerboard creates the effect of flickering lights.
Study: NCT06099158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeartLogic
Description: HeartLogic alerts will be managed according to a standardized alert management guide to ensure uniform reactions to HeartLogic alerts.
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year
Study: NCT06002698

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root canal treatment (Control)
Description: Root canal treatment - Removal of the inflamed pulp tissues from the whole root canals of the tooth.
Study: NCT05350176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsules will be composed of 10 billion CFU of Lactobacillus plantarum.
Study: NCT06002698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full pulpotomy (Experimental)
Description: Full pulpotomy - Removal of the inflamed coronal pulp tissues from the crown of the tooth.
Study: NCT04989166

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nano-curcumin
Description: Nano-curcumin soft gels
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year
Study: NCT05350176

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing dextrose (1 capsule per day)
Study: NCT04989166

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05618431

Intervention type: OTHER
Group type: OTHER
Intervention: NIPT
Description: This research aims to develop and validate a new method for non-invasive prenatal testing
Study: NCT06682650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NPT-PLA
Description: NPT-PLA was developed and initially tested in 5 European countries in the EU-funded RESTORE study. PLA Participatory Learning in Action is a set of participatory research techniques in which participants use democratic processes to identify key actions needed to achieve a specific goal e.g. implementation of a tested decision making tool such as I2; and prioritize which of these need to be acted upon first and subsequently (in which order). Normalization Process Theory (NPT) is combined with PLA to help implementation teams using PLA to assess organization capacity and readiness to enact the selected action steps vis-a-vis NPT constructs, iteratively. These are coherence does everyone understand what needs to be done?; Cognitive participation Does everyone who needs to act 'buy in' to take action; collective action Is everyone who needs to act taking steps to make the change?'; and reflexive monitoring After the step has been taken, has it had the desired impact on the goal?

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Quality Improvement
Description: Usual quality improvement includes principles of continuous quality improvement, such as Plan-Do-Study-Act cycles, to implement a specific goal. In this study, 'usual QI' methods already in use in 'active comparator' arm will be documented during the baseline assessment of clinical workflows in clinics assigned to that arm; and will be provided with a 'preset protocol' to implement the study shared decision-making tool (I2). Processes that implementation teams in these clinics use to achieve implementation will be documented.
Study: NCT06199830

Intervention type: DIAGNOSTIC_TEST
Intervention: positive bronchial provocation test
Description: Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation. This test was stopped until a reducing in baseline FEV1 of 20%.
Study: NCT05428670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib+Rituximab+Lenalidomide
Description: Zanubrutinib is a bruton' s tyrosine kinase inhibitor independently developed in China.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCHOP/RCDOP
Description: RCHOP/RCDOP is the classic treatment of diffuse large B cell lymphoma.
Study: NCT05522400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) and human computer interaction system
Description: The experimental group used VR technology and human-computer interaction system for exercise, while the control group used traditional exercise program
Study: NCT06421441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Management Skills Training
Description: Nursing students will be given self-management skills training for a total of 12 hours, two days a week, two hours a day (60 min. + 60 min.) for three weeks.
Study: NCT06063720

Intervention type: DEVICE
Intervention: Endoscreen QC
Description: Artificial intelligence monitoring of effective withdrawal time
Study: NCT06570499

Intervention type: OTHER
Group type: OTHER
Intervention: Implant impression
Description: definitive impressions on implants
Study: NCT06570031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abemaciclib
Description: Specified dose on specified days
Study: NCT03841474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment with sertraline
Description: Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychiatric treatment with escitalopram
Description: Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
Study: NCT05420467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, d1, q3w,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, d1, q3w,6 cycles
Study: NCT05516953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen Tablets
Description: 10 mg oral baclofen 1 h before anesthesia
Study: NCT06684106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg
Description: UDCA together with statin in eligible participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo together with statin in ASCVD patients
Study: NCT05420467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6, d1, q3w,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, d1, q3w,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: starting dose 8 mg/kg, maintenance dose 6 mg/kg, d1, q3w,6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: starting dose of 840 mg, maintenance dose of 420 mg, d1, q3w ,6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 220 mg/m2, d1, q3w,6 cycles
Study: NCT06409585

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI at 1 year
Study: NCT05420467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 220 mg/m2, d1, q3w,6 cycles
Study: NCT06695650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala Coloring
Description: Students in the intervention group will be provided with mandala templates and coloring materials. They will be asked to color for 15 minutes twice a week over a two-month period
Study: NCT06694701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emapalumab-Izsg
Description: The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emapalumab-Izsg
Description: The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
Study: NCT06701721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN391 MAD
Description: Route of administration- IVT injection
Study: NCT06701656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort C: bevacizumab
Description: Administered as a single IV dose of 500 mg on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort C: placebo
Description: Administered as a single IV dose of placebo on Day 1
Study: NCT06703242

Intervention type: OTHER
Group type: OTHER
Intervention: Health promotion for mothers of children with ADHD in the ultra-orthodox community
Description: The intervention will consist of 3 modules with six sessions. Mothers will gain knowledge in topics related to understanding the ADHD health condition and its biological origins, optimal and recommended treatment options, school management techniques, and the importance of taking care of their own health.
Study: NCT06710392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme Cocktail A
Description: Enzyme cocktail A in the form of a capsule with a daily dose of 275mg taken 3 times a day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enzyme Cocktail B
Description: Enzyme cocktail B in the form of a capsule with a daily dose of 50mg taken 3 times a day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo A
Description: Placebo A matching investigational product A given 3 times a day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo B
Description: Placebo B matching investigational product B given 3 times a day for 4 weeks.
Study: NCT06708468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention includes 12-day personalized exercise program set in a rehabilitation center, followed by a three-month digital intervention and then a second 12-day personalized exercise program in a rehabilitation center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes appointments at hospitals and in the community health system according to what has been recommended to that individual